Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
 235,000
 +14,000 (6.33%)
  Oct 31, 2025, 1:40 PM KST
Sam Chun Dang Pharm. Revenue
Sam Chun Dang Pharm. had revenue of 56.90B KRW in the quarter ending June 30, 2025, with 3.66% growth. This brings the company's revenue in the last twelve months to 215.10B, up 5.29% year-over-year. In the year 2024, Sam Chun Dang Pharm. had annual revenue of 210.92B with 9.47% growth.
Revenue (ttm) 
 215.10B
Revenue Growth 
 +5.29%
P/S Ratio 
 23.90
Revenue / Employee 
 513.35M
Employees 
 419
Market Cap 
5.14T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% | 
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% | 
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% | 
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% | 
| Dec 31, 2020 | 166.86B | -19.74B | -10.58% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| Hanmi Pharm. | 1.47T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |